Predictive factors in Capecitabine plus CDDP therapy in patients with HER2 negative advanced gastric cancer.

Trial Profile

Predictive factors in Capecitabine plus CDDP therapy in patients with HER2 negative advanced gastric cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Aug 2012 Planned end date changed from 1 Jul 2013 to 31 Aug 2014 as reported by University Hospital Medical Information Network - Japan.
    • 04 Apr 2012 Planned end date (Jul 2013) added as reported by University Hospital Medical Information Network - Japan.
    • 05 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top